![logo](/logos/FUSN.webp)
Fusion Pharmaceuticals Inc.
NASDAQ:FUSN
21.55 (USD) • At close June 4, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Fusion Pharmaceuticals Inc. |
Symbool | FUSN |
Munteenheid | USD |
Prijs | 21.55 |
Beurswaarde | 1,833,043,000 |
Dividendpercentage | 0% |
52-weken bereik | 2.31 - 21.6 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. John F. Valliant Ph.D. |
Website | https://fusionpharma.com |
An error occurred while fetching data.
Over Fusion Pharmaceuticals Inc.
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)